SPOTLIGHT -
CAR T-cell Therapy Shows 6-Year Durability in CLL Patients
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.
Read More